Do hybrid procedures have proven clinical utility and are they the wave of the future?: Hybrid procedures have no proven clinical utility and are not the wave of the future

Circulation

Volumn 125, Issue 20, 2012, Pages 2504-2510

  Leacche, Marzia ^a   Zhao, David X ^a   Umakanthan, Ramanan ^a   Byrne, John G ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOPIDOGREL; HEPARIN; TICLOPIDINE;

ARTICLE; BLEEDING; CORONARY ARTERY BYPASS GRAFT; HEART MUSCLE REVASCULARIZATION; HUMAN; IN-STENT RESTENOSIS; LEFT ANTERIOR DESCENDING CORONARY ARTERY; PERCUTANEOUS CORONARY INTERVENTION; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; STENT THROMBOSIS; THERAPY EFFECT;

ANGIOPLASTY, BALLOON, CORONARY; CARDIOLOGY; CORONARY ARTERY BYPASS; CORONARY ARTERY DISEASE; CORONARY RESTENOSIS; GRAFT SURVIVAL; HUMANS; PLATELET AGGREGATION INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STENTS;

EID: 84861314036     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.111.031138     Document Type: Article

References (48)

1. Bypass Angioplasty Revascularization Investigation (BARI) Investigators. Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. N Engl J Med. 1996;335:217-225.
2. Serruys PW, Morice MC, Kappetein AP, Colombo A, Holmes DR, Mack MJ, St°hle E, Feldman TE, van den Brand M, Bass EJ, Van Dyck N, Leadley K, Dawkins KD, Mohr FW; SYNTAX Investigators. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med. 2009;360:961-972.
3. Bypass Angioplasty Revascularization Investigation (BARI) Investigators. BARI trial: the final 10-year follow-up results from the BARI randomized trial. J Am Coll Cardiol. 2007;49:1600-1606.
4. Alexander JH, Hafley G, Harrington RA, Peterson ED, Ferguson TB Jr, Lorenz TJ, Goyal A, Gibson M, Mack MJ, Gennevois D, Califf RM, Kouchoukos NT; PREVENT IV Investigators. Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery: PREVENT IV: a randomized controlled trial. JAMA. 2005;294:2446-2454.
5. Puskas JD, Williams WH, Mahoney EM, Huber PR, Block PC, Duke PG, Staples JR, Glas KE, Marshall JJ, Leimbach ME, McCall SA, Petersen RJ, Bailey DE, Weintraub WS, Guyton RA. Off-pump vs conventional coronary artery bypass grafting: early and 1-year graft patency, cost, and quality-of-life outcomes: a randomized trial. JAMA. 2004;291:1841-1849.
6. Balacumaraswami L, Taggart DP. Intraoperative imaging techniques to assess coronary artery bypass graft patency. Ann Thorac Surg. 2007;83: 2251-2257.
7. Grube E, Silber S, Hauptmann KE, Mueller R, Buellesfeld L, Gerckens U, Russell ME. TAXUS I: six-and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions. Circulation. 2003;107:38-42.
8. Silber S, Colombo A, Banning AP, Hauptmann K, Drzewiecki J, Grube E, Dudek D, Baim DS. Final 5-year results of the TAXUS II trial: a randomized study to assess the effectiveness of slow-and moderaterelease polymer-based paclitaxel-eluting stents for de novo coronary artery lesions. Circulation. 2009;120:1498-1504.
9. Meredith IT, Ormiston J, Whitbourn R, Kay IP, Muller D, Cutlip DE; ENDEAVOR I Investigators. Five-year clinical follow-up after implantation of the Endeavor zotarolimus-eluting stent: ENDEAVOR I, firstin-human study. Catheter Cardiovasc Interv. 2009;74:989-995.
10. Fajadet J, Wijns W, Laarman GJ, Kuck KH, Ormiston J, Baldus S, Hauptmann KE, Suttorp MJ, Drzewiecki J, Pieper M, Schultheiss HP, Mauri L. Long-term follow-up of the randomised controlled trial to evaluate the safety and efficacy of the zotarolimus-eluting driver coronary stent in de novo native coronary artery lesions: five year outcomes in the ENDEAVOR II study. EuroIntervention. 2010;6:562-567.
11. Kandzari DE, Mauri L, Popma JJ, Turco MA, Gurbel PA, Fitzgerald PJ, Leon MB. Late-term clinical outcomes with zotarolimus-and sirolimuseluting stents: 5-year follow-up of the ENDEAVOR III (A Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions). JACC Cardiovasc Interv. 2011;4:543-550.
12. Serruys PW, Ong AT, Piek JJ, Neumann FJ, van der Giessen WJ, Wiemer M, Zeiher A, Grube E, Haase J, Thuesen L, Hamm C, Otto-Terlouw PC. A randomized comparison of a durable polymer everolimus-eluting stent with a bare metal coronary stent: the SPIRIT first trial. EuroIntervention. 2005; 1:58-65.
13. Serruys PW, Ruygrok P, Neuzner J, Piek JJ, Seth A, Schofer JJ, Richardt G, Wiemer M, Carrié D, Thuesen L, Boone E, Miquel-Herbert K, Daemen J. A randomised comparison of an everolimus-eluting coronary stent with a paclitaxel-eluting coronary stent: the SPIRIT II trial. EuroIntervention. 2006;2:286-294.
14. Stone GW, Midei M, Newman W, Sanz M, Hermiller JB, Williams J, Farhat N, Mahaffey KW, Cutlip DE, Fitzgerald PJ, Sood P, Su X, Lansky AJ; SPIRIT III Investigators. Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial. JAMA. 2008;299:1903-1913.
15. Sabik JF 3rd, Lytle BW, Blackstone EH, Houghtaling PL, Cosgrove DM. Comparison of saphenous vein and internal thoracic artery graft patency by coronary system. Ann Thorac Surg. 2005;79:544-551.
16. Cho KR, Jeong DS, Kim KB. Influence of vein graft use on postoperative 1-year results after off-pump coronary artery bypass surgery. Eur J Cardiothorac Surg. 2007;32:718-723.
17. Desai ND, Naylor CD, Kiss A, Cohen EA, Feder-Elituv R, Miwa S, Radhakrishnan S, Dubbin J, Schwartz L, Fremes SE; Radial Artery Patency Study Investigators. Impact of patient and target-vessel characteristics on arterial and venous bypass graft patency: insight from a randomized trial. Circulation. 2007;115:684-691.
18. Kim KB, Cho KR, Jeong DS. Midterm angiographic follow-up after off-pump coronary artery bypass: serial comparison using early, 1-year, and 5-year postoperative angiograms. J Thorac Cardiovasc Surg. 2008;135:300-307.
19. Lloyd CT, Calafiore AM, Wilde P, Ascione R, Paloscia L, Monk CR, Angelini GD. Integrated left anterior small thoracotomy and angioplasty for coronary artery revascularization. Ann Thorac Surg. 1999;68:908-912.
20. Isomura T, Suma H, Horii T, Sato T, Kobashi T, Kanemitsu H. Minimally invasive coronary artery revascularization: off-pump bypass grafting and the hybrid procedure. Ann Thorac Surg. 2000;70:2017-2022.
21. De Canniere D, Jansens JL, Goldschmidt-Clermont P, Barvais L, Decroly P, Stoupel E. Combination of minimally invasive coronary bypass and percutaneous transluminal coronary angioplasty in the treatment of double-vessel coronary disease: two-year follow-up of a new hybrid procedure compared with "on-pump" double bypass grafting. Am Heart J. 2001;142:563-570.
22. Presbitero P, Nicolini F, Maiello L, Franciosi G, Carcagni A, Milone F, Manasse E, Gallotti R. "Hybrid" percutaneous and surgical coronary revascularization: selection criteria from a single-center experience. Ital Heart J. 2001;2:363-368.
23. Cisowski M, Morawski W, Drzewiecki J, Bochenek A. Integrated minimally invasive direct coronary artery bypass grafting and angioplasty for coronary artery revascularization. Eur J Cardiothorac Surg. 2002;22:261-265.
24. Stahl KD, Boyd WD, Vassiliades TA, Karamanoukian HL. Hybrid robotic coronary artery surgery and angioplasty in multivessel coronary artery disease. Ann Thorac Surg. 2002;74:S1358-1362.
25. Angelini GD, Taylor FC, Reeves BC, Ascione R. Early and midterm outcome after off-pump and on-pump surgery in Beating Heart Against Cardioplegic Arrest Studies (BHACAS 1 and 2): a pooled analysis of two randomized controlled trials. Lancet. 2002;359:1194-1199.
26. Lewis BS, Porat E, Halon DA, Ammar R, Flugelman MY, Khader N, Merdler A, Weisz G, Uretzky G. Same-day combined coronary angioplasty and minimally invasive coronary surgery. Am J Cardiol. 1999;84: 1246-1247, A8.
27. Wittwer T, Cremer J, Klima U, Wahlers T, Haverich A. Myocardial "hybrid" revascularization: intermediate results of an alternative approach to multivessel coronary artery disease. J Thorac Cardiovasc Surg. 1999; 118:766-767.
28. Riess FC, Bader R, Kremer P, Kühn C, Kormann J, Mathey D, Moshar S, Tuebler T, Bleese N, Schofer J. Coronary hybrid revascularization from January 1997 to January 2001: a clinical follow-up. Ann Thorac Surg. 2002;73:1849-1855.
29. Zenati M, Cohen HA, Griffith BP. Alternative approach to multivessel coronary disease with integrated coronary revascularization. J Thorac Cardiovasc Surg. 1999;117:439-446.
30. Us MH, Basaran M, Yilmaz M, Yaymaci B, Ulusoy E, Sanioglu S, Ozbek C, Arslan Y, Pocan S, Yilmaz AT. Hybrid coronary revascularization in high-risk patients. Tex Heart Inst J. 2006;33:458-462.
31. Gilard M, Bezon E, Cornily JC, Mansourati J, Mondine P, Barra JA, Boschat J. Same-day combined percutaneous coronary intervention and coronary artery surgery. Cardiology. 2007;108:363-367.
32. Kon ZN, Brown EN, Tran R, Joshi A, Reicher B, Grant MC, Kallam S, Burris N, Connerney I, Zimrin D, Poston RS. Simultaneous hybrid coronary revascularization reduces postoperative morbidity compared with results from conventional off-pump coronary artery bypass. J Thorac Cardiovasc Surg. 2008;135:367-375.
33. Reicher B, Poston RS, Mehra MR, Joshi A, Odonkor P, Kon Z, Reyes PA, Zimrin DA. Simultaneous "hybrid" percutaneous coronary intervention and minimally invasive surgical bypass grafting: feasibility, safety, and clinical outcomes. Am Heart J. 2008;155:661-667.
34. Hu S, Li Q, Gao P, Xiong H, Zheng Z, Li L, Xu B, Gao R. Simultaneous hybrid revascularization versus off-pump coronary artery bypass for multivessel coronary artery disease. Ann Thorac Surg. 2011;91:432-438.
35. Lee MS, Wilentz JR, Makkar RR, Singh V, Nero T, Swistel D, Belsey SJ, Simon C, Rametta S, DeRose J. Hybrid revascularization using percutaneous coronary intervention and robotically assisted minimally invasive direct coronary artery bypass surgery. J Invasive Cardiol. 2004;16: 419-425.
36. Davidavicius G, Van Praet F, Mansour S, Casselman F, Bartunek J, Degrieck I, Wellens F, De Geest R, Vanermen H, Wijns W, De Bruyne B. Hybrid revascularization strategy: a pilot study on the association of robotically enhanced minimally invasive direct coronary artery bypass surgery and fractional-flow-reserve-guided percutaneous coronary intervention. Circulation. 2005;112(suppl):I-317-I-322.
37. Kiaii B, McClure RS, Kostuk WJ, Rayman R, Swinamer S, Dobkowski WB, Novick RJ. Concurrent robotic hybrid revascularization using an enhanced operative suite. Chest. 2005;128:4046-4048.
38. Katz MR, Van Praet F, de Canniere D, Murphy D, Siwek L, Seshadri-Kreaden U, Friedrich G, Bonatti J. Integrated coronary revascularization: percutaneous coronary intervention plus robotic totally endoscopic coronary artery bypass. Circulation. 2006;114:I473-I476.
39. Vassiliades TA Jr, Douglas JS, Morris DC, Block PC, Ghazzal Z, Rab ST, Cates CU. Integrated coronary revascularization with drug-eluting stents: immediate and seven-month outcome. J Thorac Cardiovasc Surg. 2006; 131:956-962.
40. Bonatti J, Schachner T, Bonaros N, Jonetzko P, Ohlinger A, Ruetzler E, Kolbitsch C, Feuchtner G, Laufer G, Pachinger O, Friedrich G. Simultaneous Hybrid COronary Revascularization Using Totally Endoscopic Left Internal Mammary Artery Bypass Grafting and Placement of RapamycIN Eluting Stents in the SAme IntervenTIONal Session: the COMBINATION pilot study. Cardiology. 2007;110:92-95.
41. Holzhey DM, Jacobs S, Mochalski M, Merk D, Walther T, Mohr FW, Falk V. Minimally invasive hybrid coronary artery revascularization. Ann Thorac Surg. 2008;86:1856-1860.
42. Zhao DX, Leacche M, Balaguer JM, Boudoulas KD, Damp JA, Greelish JP, Byrne JG; Writing Group of the Cardiac Surgery, Cardiac Anesthesiology, and Interventional Cardiology Groups at the Vanderbilt Heart and Vascular Institute, Ahmad RM, Ball SK, Cleator JH, Deegan RJ, Eagle SS, Fong PP, Fredi JL, Hoff SJ, Jennings HS 3rd, McPherson JA, Piana RN, Pretorius M, Robbins MA, Slosky DA, Thompson A. Routine intraoperative completion angiography after coronary artery bypass grafting and 1-stop hybrid revascularization results from a fully integrated hybrid catheterization laboratory/operating room. J Am Coll Cardiol. 2009;53:232-241.
43. Morice MC, Serruys PW, Kappetein AP, Feldman TE, Ståhle E, Colombo A, Mack MJ, Holmes DR, Torracca L, van Es GA, Leadley K, Dawkins KD, Mohr F. Outcomes in patients with de novo left main disease treated with either percutaneous coronary intervention using paclitaxel-eluting stents or coronary artery bypass graft treatment in the Synergy Between Percutaneous Coronary Intervention With TAXUS and Cardiac Surgery (SYNTAX) trial. Circulation. 2010;121:2645-2653.
44. Yan Q, Changsheng M, Shaoping N, Xiaohui L, Junping K, Qiang L, Xin D, Rong H, Yin Z, Changqi J, Jiahui W, Xinmin L, Jianzeng D, Fang C, Yujie Z, Shuzheng L, Fangjiong H, Chengxiong G, Xuesi W. Percutaneous treatment with drug-eluting stent vs bypass surgery in patients suffering from chronic stable angina with multivessel disease involving significant proximal stenosis in left anterior descending artery. Circ J. 2009;73:1848-1855.
45. Banning AP, Westaby S, Morice MC, Kappetein AP, Mohr FW, Berti S, Glauber M, Kellett MA, Kramer RS, Leadley K, Dawkins KD, Serruys PW. Diabetic and nondiabetic patients with left main and/or 3-vessel coronary artery disease: comparison of outcomes with cardiac surgery and paclitaxel-eluting stents. J Am Coll Cardiol. 2010;55:1067-1075.
46. Byrne JG, Leacche M, Vaughan DE, Zhao DX. Hybrid cardiovascular procedures. JACC Cardiovasc Interv. 2008;1:459-468.
47. Farkouh ME, Dangas G, Leon MB, Smith C, Nesto R, Buse JB, Cohen DJ, Mahoney E, Sleeper L, King S 3rd, Domanski M, McKinlay S, Fuster V. Design of the Future REvascularization Evaluation in patients with Diabetes mellitus: optimal management of Multivessel disease (FREEDOM) Trial. Am Heart J. 2008;155:215-223.
48. Taggart DP. Lessons learned from the SYNTAX trial for multivessel and left main stem coronary artery disease. Curr Opin Cardiol. 2011;26:502-507.